Skip to content
Screener

Boston Scientific BSX Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

TFX
TeleflexTFX
-$67K-100%
Globus Medical logo
Globus MedicalGMED
$9.71M+85.9%
CONMED logo
CONMEDCNMD
——
Merit Medical Systems logo
Merit Medical SystemsMMSI
——
Stereotaxis logo
StereotaxisSTXS
——

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.46B-52.2%
P/E19.5×-40.4×
P/S3.4×-4.7×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions, except per share data)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development expenses516443
Royalty expense1214
Amortization expense232219
Contingent consideration net expense (benefit)(30)5
Restructuring net charges (credits)310
2,5132,288
Operating income (loss)1,101921
Other income (expense):

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's contingent consideration fair value adjustments?
Boston Scientific (BSX) reported contingent consideration fair value adjustments of -$30M in Q1 2026.
How has Boston Scientific's contingent consideration fair value adjustments changed year-over-year?
Boston Scientific's contingent consideration fair value adjustments decreased by 700.0% year-over-year, from $5M to -$30M.
What is the long-term trend for Boston Scientific's contingent consideration fair value adjustments?
Over 3 years (2021 to 2025), Boston Scientific's contingent consideration fair value adjustments has grown at a -49.0% compound annual growth rate (CAGR), from -$136M to $18M.
What does contingent consideration fair value adjustments mean?
This represents adjustments to the fair value of earn-out payments owed to sellers of acquired businesses. These adjustments reflect changes in the probability or timing of meeting performance milestones post-acquisition.

Ask your AI about Boston Scientific's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude